[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-001", "question": "A 71-year-old woman with a dual-chamber pacemaker (DDDR) for sick sinus syndrome presents with episodic dizziness and syncope. Device interrogation reveals normal lead parameters but frequent pacemaker-mediated tachycardia (PMT) episodes terminated by the device's algorithm. However, she continues to report symptoms. Telemetry shows intermittent 2:1 AV block during atrial tracking, with every second P wave falling within post-ventricular atrial refractory period (PVARP). Which programming adjustment will most effectively eliminate symptoms while preserving maximal atrioventricular synchrony?", "options": ["Extend PVARP by 50 ms", "Enable dynamic PVARP extension after premature ventricular contractions", "Reduce upper tracking limit to 120 bpm", "Switch to DDI mode at rest", "Enable atrial preference pacing"], "answer": "B", "answer_index": 1, "explanation": "Dynamic PVARP extension after PVCs prevents retrograde conduction from initiating PMT while preserving atrial tracking during sinus rhythm. Extending PVARP statically (A) would worsen 2:1 block and cause pacemaker syndrome. Reducing upper tracking (C) does not prevent PMT initiation. DDI mode (D) eliminates atrial tracking entirely. Atrial preference pacing (E) is irrelevant to PMT prevention.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 71-year-old with DDDR pacemaker for sick sinus syndrome, episodic dizziness/syncope, normal lead parameters, frequent PMT episodes terminated by algorithm but persistent symptoms, telemetry showing intermittent 2:1 AV block during atrial tracking with every second P wave in PVARP. These indicate PMT likely initiated by retrograde conduction post-PVC, causing symptoms despite termination, with need for adjustment preserving AV synchrony. Main logical issue(s): None; stem provides sufficient details for discriminating B as uniquely best by enabling dynamic PVARP extension after PVCs to prevent PMT initiation without static changes that worsen block or reduce tracking. Alternatives are inferior: A statically extends PVARP, exacerbating 2:1 block; C limits tracking rate but doesn't address PMT trigger; D switches to DDI, losing atrial tracking; E enables atrial preference pacing, irrelevant to PMT. Main medical accuracy issue(s): None; aligns with standard pacemaker management per guidelines (e.g., HRS/ACC), where dynamic PVARP post-PVC prevents retrograde P-wave sensing initiating PMT while maintaining synchrony. Minimal fix: Not needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 71-year-old with DDDR pacemaker for sick sinus syndrome, episodic dizziness/syncope, normal lead parameters, frequent PMT episodes terminated by algorithm but persistent symptoms, telemetry showing intermittent 2:1 AV block during atrial tracking with every second P wave in PVARP. These indicate PMT likely initiated by retrograde conduction post-PVC, causing symptoms despite termination, with need for adjustment preserving AV synchrony. Main logical issue(s): None; stem provides sufficient details for discriminating B as uniquely best by enabling dynamic PVARP extension after PVCs to prevent PMT initiation without static changes that worsen block or reduce tracking. Alternatives are inferior: A statically extends PVARP, exacerbating 2:1 block; C limits tracking rate but doesn't address PMT trigger; D switches to DDI, losing atrial tracking; E enables atrial preference pacing, irrelevant to PMT. Main medical accuracy issue(s): None; aligns with standard pacemaker management per guidelines (e.g., HRS/ACC), where dynamic PVARP post-PVC prevents retrograde P-wave sensing initiating PMT while maintaining synchrony. Minimal fix: Not needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-002", "question": "A 42-year-old man with a heterozygous CSF1R p.Arg782His mutation and early-stage adult-onset leukoencephalopathy with axonal spheroids (ALSP) has mild cognitive impairment and gait instability. His sister progressed to severe dementia within 3 years of symptom onset. Which intervention has demonstrated the highest disease-modifying efficacy when performed before onset of severe motor disability?", "options": ["Intravenous immunoglobulin monthly", "Oral cyclophosphamide 2 mg/kg/day", "Allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor", "Ruxolitinib 20 mg twice daily", "Supportive care with donepezil"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic HSCT is the only intervention shown to halt ALSP progression when performed early, before severe disability, by replacing microglial precursors. IVIG (A) and cyclophosphamide (B) lack efficacy. Ruxolitinib (D) has no clinical data. Supportive care (E) does not modify disease course. Delay until severe motor impairment predicts transplant failure.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 42-year-old man with heterozygous CSF1R p.Arg782His mutation confirming ALSP diagnosis; early-stage with mild cognitive impairment and gait instability; family history of rapid progression to severe dementia; question seeks intervention with highest disease-modifying efficacy before severe motor disability. These clues point to early intervention to halt microglial dysfunction in ALSP. The keyed answer C (allogeneic HSCT from HLA-matched sibling) fits as it replaces defective microglial precursors, with case reports showing progression halt when done early. Alternatives: A (IVIG) lacks efficacy data; B (cyclophosphamide) not supported for ALSP; D (ruxolitinib) has no clinical evidence; E (donepezil) is symptomatic only, not disease-modifying. No main logical issues: stem is consistent, allows unique best answer without contradictions or underspecification. No main medical accuracy issues: aligns with emerging evidence on HSCT for ALSP (e.g., case series showing benefit pre-disability), consistent with mainstream standards for this rare condition; other options correctly dismissed. Minimal fix: No edit required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 42-year-old man with heterozygous CSF1R p.Arg782His mutation confirming ALSP diagnosis; early-stage with mild cognitive impairment and gait instability; family history of rapid progression to severe dementia; question seeks intervention with highest disease-modifying efficacy before severe motor disability. These clues point to early intervention to halt microglial dysfunction in ALSP. The keyed answer C (allogeneic HSCT from HLA-matched sibling) fits as it replaces defective microglial precursors, with case reports showing progression halt when done early. Alternatives: A (IVIG) lacks efficacy data; B (cyclophosphamide) not supported for ALSP; D (ruxolitinib) has no clinical evidence; E (donepezil) is symptomatic only, not disease-modifying. No main logical issues: stem is consistent, allows unique best answer without contradictions or underspecification. No main medical accuracy issues: aligns with emerging evidence on HSCT for ALSP (e.g., case series showing benefit pre-disability), consistent with mainstream standards for this rare condition; other options correctly dismissed. Minimal fix: No edit required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic hemangiopericytoma, refractory hypoglycemia despite dextrose, suppressed insulin/C-peptide, elevated IGF-2, and high IGF-2:IGF-1 ratio, pointing to non-islet cell tumor hypoglycemia (NICTH) from tumor-derived IGF-2. These findings support immediate intervention targeting IGF-2 effects or production. The keyed answer A (hydrocortisone infusion) fits as high-dose glucocorticoids suppress tumor IGF-2 production and increase IGF-binding proteins, rapidly correcting hypoglycemia in NICTH, consistent with standard management. Alternatives: B (recombinant IGF-1) may normalize ratios but is not first-line, experimental, and could theoretically exacerbate imbalance per rationale; C (diazoxide) and D (octreotide) target insulin secretion, ineffective here with already suppressed insulin; E (glucagon) offers only transient glycemic support unsuitable for sustained euglycemia. No main logical issues; stem allows discrimination of A as uniquely best without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., Endocrine Society) where glucocorticoids are mainstay for acute NICTH management, though rhIGF-1 has limited supportive evidence in refractory cases without regional variation affecting best answer. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include metastatic hemangiopericytoma, refractory hypoglycemia despite dextrose, suppressed insulin/C-peptide, elevated IGF-2, and high IGF-2:IGF-1 ratio, pointing to non-islet cell tumor hypoglycemia (NICTH) from tumor-derived IGF-2. These findings support immediate intervention targeting IGF-2 effects or production. The keyed answer A (hydrocortisone infusion) fits as high-dose glucocorticoids suppress tumor IGF-2 production and increase IGF-binding proteins, rapidly correcting hypoglycemia in NICTH, consistent with standard management. Alternatives: B (recombinant IGF-1) may normalize ratios but is not first-line, experimental, and could theoretically exacerbate imbalance per rationale; C (diazoxide) and D (octreotide) target insulin secretion, ineffective here with already suppressed insulin; E (glucagon) offers only transient glycemic support unsuitable for sustained euglycemia. No main logical issues; stem allows discrimination of A as uniquely best without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., Endocrine Society) where glucocorticoids are mainstay for acute NICTH management, though rhIGF-1 has limited supportive evidence in refractory cases without regional variation affecting best answer. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Patient with rheumatoid arthritis on methotrexate presents with progressive dyspnea and weight loss; HRCT shows upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis, and severe volume loss; biopsy reveals dense subpleural fibrosis with prominent elastic fiber deposition, minimal inflammation, extending into pleura. These point to pleuroparenchymal fibroelastosis (PPFE), differentiated from usual interstitial pneumonia (UIP) by visceral pleural and subpleural elastosis (option D).\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (e.g., upper lobe predominance, elastic fiber deposition, minimal inflammation) to identify D as uniquely best, with alternatives representing UIP hallmarks (A, B, E) or unrelated features (C).\\nMain medical accuracy issue(s), if any: None; aligns with current standards for PPFE diagnosis (e.g., ATS/ERS guidelines on idiopathic interstitial pneumonias), where elastosis is pathognomonic and absent in UIP; vignette realistically associates with RA/methotrexate exposure.\\nMinimal fix: No edit required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Patient with rheumatoid arthritis on methotrexate presents with progressive dyspnea and weight loss; HRCT shows upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis, and severe volume loss; biopsy reveals dense subpleural fibrosis with prominent elastic fiber deposition, minimal inflammation, extending into pleura. These point to pleuroparenchymal fibroelastosis (PPFE), differentiated from usual interstitial pneumonia (UIP) by visceral pleural and subpleural elastosis (option D).\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (e.g., upper lobe predominance, elastic fiber deposition, minimal inflammation) to identify D as uniquely best, with alternatives representing UIP hallmarks (A, B, E) or unrelated features (C).\nMain medical accuracy issue(s), if any: None; aligns with current standards for PPFE diagnosis (e.g., ATS/ERS guidelines on idiopathic interstitial pneumonias), where elastosis is pathognomonic and absent in UIP; vignette realistically associates with RA/methotrexate exposure.\nMinimal fix: No edit required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-005", "question": "A 26-year-old woman ingests 60 mg of colchicine in a suicide attempt, presenting 8 hours later with profuse vomiting and diarrhea. Labs: WBC 22,000/μL, platelets 600,000/μL. Which intervention, when initiated within 12 hours of ingestion, has demonstrated mortality reduction in severe colchicine poisoning?", "options": ["Colchicine-specific Fab fragments 4 g IV bolus", "Granulocyte colony-stimulating factor 5 μg/kg/day subcutaneously", "Continuous venovenous hemofiltration at 50 mL/kg/hour", "N-acetylcysteine 150 mg/kg IV loading dose", "Plasma exchange daily for 5 days"], "answer": "B", "answer_index": 1, "explanation": "Early G-CSF administration reduces mortality by preventing septic complications from bone marrow suppression that begins 24-48 hours post-ingestion. Colchicine Fab (A) is experimental and unavailable. CVVH (C) does not enhance colchicine clearance due to large volume of distribution. NAC (D) has no role. Plasma exchange (E) is ineffective for intracellular toxins.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: High-dose colchicine ingestion (60 mg), presentation at 8 hours with profuse vomiting/diarrhea, initial leukocytosis (WBC 22,000/μL) and thrombocytosis (platelets 600,000/μL), implying early phase before bone marrow suppression; question seeks intervention within 12 hours demonstrating mortality reduction in severe poisoning. The clinical problem asks for the best early intervention to mitigate mortality from anticipated complications like sepsis due to myelosuppression. Discriminating findings: Acute GI toxicity post-ingestion, labs suggesting stress response without current suppression. Most likely mechanism: Colchicine-induced microtubule disruption leading to delayed bone marrow failure. Keyed answer B (G-CSF) fits as it prevents neutropenia and septic complications, supported by case reports showing benefit when started early. Alternatives: A (Fab) experimental/unavailable; C (CVVH) ineffective due to colchicine's large Vd; D (NAC) irrelevant to colchicine; E (plasma exchange) not useful for intracellular toxin. No main logical issues; stem allows discrimination without contradictions or underspecification. Main medical accuracy issues: G-CSF use is based on observational data rather than RCTs, but aligns with toxicological consensus for supportive care in severe cases; phrasing 'demonstrated mortality reduction' may overstate evidence strength, though board-relevant. Minimal fix: None needed, but could add 'based on case series' to rationale for precision.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: High-dose colchicine ingestion (60 mg), presentation at 8 hours with profuse vomiting/diarrhea, initial leukocytosis (WBC 22,000/μL) and thrombocytosis (platelets 600,000/μL), implying early phase before bone marrow suppression; question seeks intervention within 12 hours demonstrating mortality reduction in severe poisoning. The clinical problem asks for the best early intervention to mitigate mortality from anticipated complications like sepsis due to myelosuppression. Discriminating findings: Acute GI toxicity post-ingestion, labs suggesting stress response without current suppression. Most likely mechanism: Colchicine-induced microtubule disruption leading to delayed bone marrow failure. Keyed answer B (G-CSF) fits as it prevents neutropenia and septic complications, supported by case reports showing benefit when started early. Alternatives: A (Fab) experimental/unavailable; C (CVVH) ineffective due to colchicine's large Vd; D (NAC) irrelevant to colchicine; E (plasma exchange) not useful for intracellular toxin. No main logical issues; stem allows discrimination without contradictions or underspecification. Main medical accuracy issues: G-CSF use is based on observational data rather than RCTs, but aligns with toxicological consensus for supportive care in severe cases; phrasing 'demonstrated mortality reduction' may overstate evidence strength, though board-relevant. Minimal fix: None needed, but could add 'based on case series' to rationale for precision.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-006", "question": "A 55-year-old man with severe Barlow's disease undergoes 3D transesophageal echocardiography for mitral valve repair planning. The surgeon asks you to identify the parameter that best predicts durable repair. Which measurement most strongly correlates with successful leaflet coaptation after annuloplasty?", "options": ["Anterior leaflet length >35 mm", "Posterior leaflet thickness >5 mm", "Annular height to commissural width ratio >0.3", "Flail gap distance <10 mm", "Coaptation depth >15 mm"], "answer": "C", "answer_index": 2, "explanation": "Annular height to commissural width ratio >0.3 indicates adequate leaflet tissue and annular dynamics, predicting successful repair. Excessive leaflet length (A) and thickness (B) increase complexity but do not predict success. Flail gap (D) and coaptation depth (E) are important but secondary to annular geometry in Barlow's disease where tissue redundancy is the primary pathology.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old man with severe Barlow's disease undergoing 3D transesophageal echocardiography for mitral valve repair planning; question seeks parameter best predicting durable repair via successful leaflet coaptation after annuloplasty. These clues emphasize annular geometry in Barlow's, characterized by bileaflet prolapse and tissue redundancy, making annular height to commissural width ratio (>0.3) the strongest correlate for preserved saddle shape and repair success. No main logical issues: stem is consistent, supports unique best answer (C), with distinct options allowing discrimination without contradictions or underspecification. No main medical accuracy issues: keyed answer aligns with current cardiothoracic guidelines (e.g., AHA/ACC) on mitral valve repair in degenerative disease, where annular non-planarity ratio predicts coaptation and durability; rationale correctly notes secondary role of leaflet metrics (A, B) and regurgitation parameters (D, E). Item is clinically realistic and board-relevant. Minimal fix: None required, as item is already unambiguous and accurate; optionally, add 'in Barlow's disease' to option C for emphasis, but not necessary.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old man with severe Barlow's disease undergoing 3D transesophageal echocardiography for mitral valve repair planning; question seeks parameter best predicting durable repair via successful leaflet coaptation after annuloplasty. These clues emphasize annular geometry in Barlow's, characterized by bileaflet prolapse and tissue redundancy, making annular height to commissural width ratio (>0.3) the strongest correlate for preserved saddle shape and repair success. No main logical issues: stem is consistent, supports unique best answer (C), with distinct options allowing discrimination without contradictions or underspecification. No main medical accuracy issues: keyed answer aligns with current cardiothoracic guidelines (e.g., AHA/ACC) on mitral valve repair in degenerative disease, where annular non-planarity ratio predicts coaptation and durability; rationale correctly notes secondary role of leaflet metrics (A, B) and regurgitation parameters (D, E). Item is clinically realistic and board-relevant. Minimal fix: None required, as item is already unambiguous and accurate; optionally, add 'in Barlow's disease' to option C for emphasis, but not necessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-007", "question": "A 67-year-old man presents with 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, and gait instability. Polysomnography shows severe sleep fragmentation with complete loss of REM sleep. Anti-IgLON5 antibodies are positive in serum and CSF. Which therapeutic strategy has demonstrated modest symptomatic benefit in this tauopathy-mediated autoimmune disorder?", "options": ["High-dose intravenous methylprednisolone 1 g daily for 5 days", "Plasma exchange every other day for 2 weeks", "Rituximab 1 g IV every 2 weeks for 2 doses", "Combined immunotherapy with steroids, IVIG, and rituximab", "Trazodone 100 mg nightly for sleep restoration"], "answer": "D", "answer_index": 3, "explanation": "Combined immunotherapy offers modest benefit in IgLON5 disease by targeting both autoimmune and inflammatory components, though tauopathy progression continues. Monotherapy with steroids (A), plasma exchange (B), or rituximab (C) alone has shown minimal efficacy. Trazodone (E) cannot restore lost REM sleep architecture in this neurodegenerative disorder.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 67-year-old with 18 months progressive insomnia, dysautonomia, bulbar dysfunction, gait instability; polysomnography showing severe sleep fragmentation and complete REM loss; positive anti-IgLON5 antibodies in serum/CSF, framing this as tauopathy-mediated autoimmune disorder. These clues unambiguously point to anti-IgLON5 disease, where combined immunotherapy (steroids, IVIG, rituximab) has shown modest symptomatic benefit per literature, distinguishing D as best.\\nMain logical issue(s), if any: None; stem provides sufficient discriminating details for single best answer without contradictions or underspecification; options allow clear discrimination, with D superior to monotherapies (A-C) or symptomatic trazodone (E).\\nMain medical accuracy issue(s), if any: None; aligns with current consensus on anti-IgLON5 encephalopathy (e.g., Neurology reviews), recognizing autoimmune-tauopathy overlap and limited but modest benefit from combined immunotherapy over monotherapies; trazodone ineffective for core REM loss.\\nMinimal fix: No edit needed; item is already unambiguous and accurate, though optionally add 'per recent case series' to rationale for enhanced board-style precision.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 67-year-old with 18 months progressive insomnia, dysautonomia, bulbar dysfunction, gait instability; polysomnography showing severe sleep fragmentation and complete REM loss; positive anti-IgLON5 antibodies in serum/CSF, framing this as tauopathy-mediated autoimmune disorder. These clues unambiguously point to anti-IgLON5 disease, where combined immunotherapy (steroids, IVIG, rituximab) has shown modest symptomatic benefit per literature, distinguishing D as best.\nMain logical issue(s), if any: None; stem provides sufficient discriminating details for single best answer without contradictions or underspecification; options allow clear discrimination, with D superior to monotherapies (A-C) or symptomatic trazodone (E).\nMain medical accuracy issue(s), if any: None; aligns with current consensus on anti-IgLON5 encephalopathy (e.g., Neurology reviews), recognizing autoimmune-tauopathy overlap and limited but modest benefit from combined immunotherapy over monotherapies; trazodone ineffective for core REM loss.\nMinimal fix: No edit needed; item is already unambiguous and accurate, though optionally add 'per recent case series' to rationale for enhanced board-style precision.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-008", "question": "A 28-year-old phenotypic female with 46,XY karyotype and complete androgen insensitivity syndrome (CAIS) due to a null androgen receptor mutation presents with hypertension (BP 165/100 mmHg) and hypokalemia (K+ 2.8 mEq/L). Plasma renin is suppressed (<0.5 ng/mL/hr) and aldosterone is elevated (35 ng/dL). Which pharmacologic agent specifically targets the underlying mineralocorticoid excess in this syndrome?", "options": ["Eplerenone 50 mg twice daily", "Spironolactone 100 mg twice daily", "Amiloride 10 mg twice daily", "Dexamethasone 0.5 mg nightly", "Finasteride 5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "In CAIS, non-aromatized androgens directly activate mineralocorticoid receptors, causing hypertension. Spironolactone (B) antagonizes this effect while also blocking residual androgen receptor activity. Eplerenone (A) is less effective at the androgen-mediated mineralocorticoid effect. Amiloride (C) treats symptoms but not the mechanism. Dexamethasone (D) suppresses ACTH but not peripheral androgen production. Finasteride (E) blocks 5-alpha-reductase, irrelevant in CAIS with absent receptor function.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 28-year-old phenotypic female with 46,XY CAIS due to null AR mutation, presenting with HTN (165/100), hypokalemia (2.8 mEq/L), suppressed renin (<0.5 ng/mL/hr), elevated aldosterone (35 ng/dL); question seeks agent targeting underlying mineralocorticoid excess in this syndrome. These drive toward primary hyperaldosteronism diagnosis, but fail to link convincingly to CAIS or discriminate between MR antagonists. Main logical issue(s): Multiple answers defensible (M) as both A (eplerenone) and B (spironolactone) are standard MR antagonists for mineralocorticoid excess; stem underspecified (U) without details explaining why excess is 'underlying' to CAIS or preferring spironolactone over eplerenone (e.g., no mention of androgen-MR interaction). Main medical accuracy issue(s): CAIS does not typically feature mineralocorticoid excess or hypertension/hypokalemia; elevated aldosterone contradicts rationale's androgen-MR activation mechanism (which would suppress aldosterone); misleads on pathophysiology, as CAIS involves AR dysfunction without adrenal effects. Minimal fix: Add stem detail like 'due to androgen cross-activation of MR with low aldosterone' and rekey if needed to make B uniquely best.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 28-year-old phenotypic female with 46,XY CAIS due to null AR mutation, presenting with HTN (165/100), hypokalemia (2.8 mEq/L), suppressed renin (<0.5 ng/mL/hr), elevated aldosterone (35 ng/dL); question seeks agent targeting underlying mineralocorticoid excess in this syndrome. These drive toward primary hyperaldosteronism diagnosis, but fail to link convincingly to CAIS or discriminate between MR antagonists. Main logical issue(s): Multiple answers defensible (M) as both A (eplerenone) and B (spironolactone) are standard MR antagonists for mineralocorticoid excess; stem underspecified (U) without details explaining why excess is 'underlying' to CAIS or preferring spironolactone over eplerenone (e.g., no mention of androgen-MR interaction). Main medical accuracy issue(s): CAIS does not typically feature mineralocorticoid excess or hypertension/hypokalemia; elevated aldosterone contradicts rationale's androgen-MR activation mechanism (which would suppress aldosterone); misleads on pathophysiology, as CAIS involves AR dysfunction without adrenal effects. Minimal fix: Add stem detail like 'due to androgen cross-activation of MR with low aldosterone' and rekey if needed to make B uniquely best.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include systemic sclerosis, NYHA IV dyspnea, RHC confirming precapillary PH (mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU), lung biopsy showing diffuse capillary proliferation without atypia (pathognomonic for pulmonary capillary hemangiomatosis, PCH, a rare WHO Group 1' PH subset), and failure of epoprostenol (prostacyclin) and macitentan (ERA). These clues imply PCH refractory to standard PAH therapies, making transplantation the intervention with greatest 5-year survival. Main logical issue(s): none; stem provides sufficient discriminating details (biopsy findings, therapy failure) to identify D as uniquely best without contradictions or underspecification. Alternatives are worse: A/B are PAH vasodilators ineffective in PCH due to risk of pulmonary edema; C assumes autoimmune basis not supported by biopsy; E is for CTEPH, contraindicated in diffuse microvascular PCH. Main medical accuracy issue(s): none; aligns with guidelines (e.g., ESC/ERS) where PCH/PVOD-like diseases are vasodilator-refractory, with lung transplant offering ~50-60% 5-year survival vs. <20% medically. Minimal fix: none needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include systemic sclerosis, NYHA IV dyspnea, RHC confirming precapillary PH (mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU), lung biopsy showing diffuse capillary proliferation without atypia (pathognomonic for pulmonary capillary hemangiomatosis, PCH, a rare WHO Group 1' PH subset), and failure of epoprostenol (prostacyclin) and macitentan (ERA). These clues imply PCH refractory to standard PAH therapies, making transplantation the intervention with greatest 5-year survival. Main logical issue(s): none; stem provides sufficient discriminating details (biopsy findings, therapy failure) to identify D as uniquely best without contradictions or underspecification. Alternatives are worse: A/B are PAH vasodilators ineffective in PCH due to risk of pulmonary edema; C assumes autoimmune basis not supported by biopsy; E is for CTEPH, contraindicated in diffuse microvascular PCH. Main medical accuracy issue(s): none; aligns with guidelines (e.g., ESC/ERS) where PCH/PVOD-like diseases are vasodilator-refractory, with lung transplant offering ~50-60% 5-year survival vs. <20% medically. Minimal fix: none needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-010", "question": "A 62-year-old man with chronic type B aortic dissection (diagnosed 3 years ago) presents with massive hemoptysis. CT angiography shows a 7 cm ulcer-like projection in the descending thoracic aorta with active contrast extravasation into the left lower lobe bronchus. He is hypotensive (BP 85/50 mmHg). Which immediate management strategy has the lowest mortality in this aortobronchial fistula complication?", "options": ["Emergent thoracotomy with open surgical repair", "Thoracic endovascular aortic repair (TEVAR) with left subclavian coverage", "TEVAR with adjunctive left subclavian artery revascularization", "Balloon tamponade of the aortic true lumen", "Massive transfusion protocol only"], "answer": "C", "answer_index": 2, "explanation": "Aortobronchial fistula requires emergent TEVAR to seal the rupture. Adjunctive left subclavian revascularization (C) prevents spinal ischemia and reduces perioperative stroke risk compared to coverage alone (B). Open repair (A) carries >80% mortality in this setting. Balloon tamponade (D) is a temporary bridge only. Transfusion alone (E) is futile without definitive hemorrhage control.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 62-year-old with chronic type B aortic dissection (3 years), massive hemoptysis, hypotension (85/50 mmHg), CTA revealing 7 cm ulcer-like projection in descending thoracic aorta with active contrast extravasation into left lower lobe bronchus, confirming aortobronchial fistula requiring urgent intervention to control hemorrhage and minimize mortality.\\nMain logical issue(s), if any: None; stem is consistent, provides discriminating findings (e.g., rupture site, instability) allowing identification of TEVAR-based strategy as superior, with options clearly differentiated by risks (high mortality in open repair, complications without revascularization, temporizing nature of balloon/transfusion).\\nMain medical accuracy issue(s), if any: Generally accurate per current guidelines (e.g., SVS/ESVS favoring TEVAR over open repair for complicated type B dissection); however, adjunctive LSA revascularization is selectively recommended based on patient risk factors (e.g., vertebral dominance), not universally, introducing minor nuance—item implies routine benefit, which aligns with reducing spinal ischemia/stroke but may overstate in emergent settings without added details.\\nMinimal fix: Add to stem: 'The projection is proximal, requiring zone 2 landing with left subclavian artery coverage' to explicitly justify need for revascularization and strengthen defensibility of C over B.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 62-year-old with chronic type B aortic dissection (3 years), massive hemoptysis, hypotension (85/50 mmHg), CTA revealing 7 cm ulcer-like projection in descending thoracic aorta with active contrast extravasation into left lower lobe bronchus, confirming aortobronchial fistula requiring urgent intervention to control hemorrhage and minimize mortality.\nMain logical issue(s), if any: None; stem is consistent, provides discriminating findings (e.g., rupture site, instability) allowing identification of TEVAR-based strategy as superior, with options clearly differentiated by risks (high mortality in open repair, complications without revascularization, temporizing nature of balloon/transfusion).\nMain medical accuracy issue(s), if any: Generally accurate per current guidelines (e.g., SVS/ESVS favoring TEVAR over open repair for complicated type B dissection); however, adjunctive LSA revascularization is selectively recommended based on patient risk factors (e.g., vertebral dominance), not universally, introducing minor nuance—item implies routine benefit, which aligns with reducing spinal ischemia/stroke but may overstate in emergent settings without added details.\nMinimal fix: Add to stem: 'The projection is proximal, requiring zone 2 landing with left subclavian artery coverage' to explicitly justify need for revascularization and strengthen defensibility of C over B.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]